Blood and skin markers to help recognize lichen planus in adults
Studies blood and tissue samples from adults with lichen planus to find disease markers.
Key facts
- Who runs it
- Institut Pasteur
- Where
- France6 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Cellular and Molecular Biomarkers in Patients With Lichen Planus
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 1 Nov 2023
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 7 groups
- Treatments tested
- Blood samples collection
- Skin or mucous membrane brushing
- Skin or mucous membrane biopsy
- Record updated
- 1 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lichen planus or a similar skin or mucous membrane condition. These include mucosal pemphigoid, Pseudopelade of Brocq, psoriasis of the nails or lichenoid graft-versus-host disease. They give blood and skin or mouth samples to study disease markers.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- People can join when they are first diagnosed, before any whole-body treatment. They can also join when the disease is getting worse.
- Earlier treatment
- No systemic (whole-body) treatment. People who stopped treatment that calms or suppresses the immune system can join.
Main reasons for not taking part
- Skin disease only in the skin folds or only on the face, because biopsies there can leave scars
- Not able to give written consent
- Not understanding spoken and written French
- Not covered by French social security or a similar scheme
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Subject coming at the time of diagnosis of the disease before any systemic treatment, or at the time of a progressive episode of the disease, without systemic treatment or after cessation of immunomodulatory or immunosuppressive treatment
- Ability to give their consent in writing
- Must understand spoken and written French
- Affiliated to the French social security or assimilated regimes
Who cannot take part
- Dermatosis exclusively localised in the skin folds or on the face (risk of scarring from biopsies)
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and histological criteria, but in some patients and in some anatomical locations, the diagnosis is difficult to make and LP may be confused with other skin conditions.
The 7 groups in the trial
- Oral lichen planus erosiveTreatment being tested
Human biological samples : * blood samples collection at visit 1 and 2 (6 month after first visit) * brushing on skin or mucous membrane lesions at visit 1 * skin or mucous membrane biopsy at visit 1 and 2
Treatment: Blood samples collection, Skin or mucous membrane brushing, and Skin or mucous membrane biopsy
- mucosal pemphigoid with oral lesionsTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1
Treatment: Blood samples collection and Skin or mucous membrane brushing
- lichen planus with scalp involvementTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1
Treatment: Blood samples collection and Skin or mucous membrane brushing
- Pseudopelade of BrocqTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1 * skin or mucous membrane biopsy at visit 1
Treatment: Blood samples collection, Skin or mucous membrane brushing, and Skin or mucous membrane biopsy
- lichen planus with nail involvementTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1
Treatment: Blood samples collection and Skin or mucous membrane brushing
- psoriasis and specific nail involvementTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1
Treatment: Blood samples collection and Skin or mucous membrane brushing
- Lichenoid graft-versus-host diseaseTreatment being tested
Human biological samples : * blood samples collection at visit 1 * brushing on skin or mucous membrane lesions at visit 1
Treatment: Blood samples collection and Skin or mucous membrane brushing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Clinical Specificity of Cellular and Molecular Biomarkers Identified in Patients With Lichen Planus
- Plain-language title
- Blood and skin markers to help recognize lichen planus in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 1 July 2025